Since both the JAK and BTK signaling pathways appear requisite for the development of GVHD, it makes sense that targeting both at the same time could elicit a stronger response than selecting one at a time, hence our use of concomitant ruxolitinib and ibrutinib. The gene discussed is BTK; the disease is graft versus host disease.